MetaVia Inc. (MTVA)
About MetaVia Inc.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Net income
- -$13.0M
- Total assets
- $11.1M
- Market cap
- $7.6M
- Operating margin
- -2687.8%
- Net margin
- -2543.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $510.0K
- Operating expenses
- $13.7M
- Operating income
- -$13.7M
- Income tax
- -$2.4M
- Net income
- -$13.0M
- EPS (basic)
- $-7.35
- EPS (diluted)
- $-7.35
Balance sheet
- Total assets
- $11.1M
- Current assets
- $10.9M
- Total liabilities
- $5.8M
- Current liabilities
- $5.6M
- Shareholders’ equity
- $5.3M
Cash flow
- Operating cash flow
- -$15.7M
- Investing cash flow
- -$2.0K
- Financing cash flow
- $10.0M
- Net cash flow
- -$5.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $7.6M
- EPS (diluted)
- $-7.35
- Shares outstanding
- 4.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 4, 2016
MetaVia Inc. (MTVA) Stock Price
- Reported a net loss of $13.0M.
- Revenue declined 45% from FY2024 to FY2025.
- Trading 90% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MetaVia Inc..
Write a review
News about MetaVia Inc.
News & sentiment via Polygon.io
MetaVia Inc.: frequently asked questions
Is MetaVia Inc. an American company?
MetaVia Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is MetaVia Inc. headquartered?
MetaVia Inc. is headquartered in Cambridge, Massachusetts, United States.
Is MetaVia Inc. publicly traded?
Yes — MetaVia Inc. is a publicly traded company. Its stock trades under the ticker symbol MTVA on the NASDAQ.
What does MetaVia Inc. do?
MetaVia Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
